Understanding TreatmentOptions in
Cutaneous Lymphoma
34
References
35
12. ApisarnthanaraxN,WoodGS, Stevens SR, et al.Phase I clinical trial of
O6-benzylguanine and topical carmustine in the treatment of cutaneous
T-cell lymphoma,mycosis fungoides type.
ArchDermatol
. 2012;148(5):613-
620.
13. PoligoneB,HealdP. Innovative therapy of cutaneousT-cell lymphoma:
beyondpsoralen and ultraviolet light andnitrogenmustard.
DermatolClin
.
2010;28(3):501-510.
14. CoorsEA, SchulerG,VonDenDrieschP.Topical imiquimod as treatment
for different kinds of cutaneous lymphoma.
Eur JDermatol
. 2006;16(4):391-
393.
15. Martinez-GonzalezMC,Verea-HernandoMM,Yebra-PimentelMT,Del
Pozo J,MazairaM, FonsecaE. Imiquimod inmycosis fungoides.
Eur J
Dermatol
. 2008;18(2):148-152.
16. BushueN,WanYJ.Retinoidpathway and cancer therapeutics.
AdvDrug
DelivRev
. 2010;62(13):1285-1298.
17. VakevaL,Ranki A,Hahtola S.Ten-year experience of bexarotene
therapy for cutaneousT-cell lymphoma inFinland.
ActaDermVenereol
.
2012;92(3):258-263.
18. SchadtCR.Topical and oral bexarotene.
DermatolTher
. 2013;26(5):400-
403.
19. Zandi S,Kalia S,LuiH.UVA1 phototherapy: a concise andpractical
review.
SkinTherapyLett
. 2012;17(1):1-4.
20. PonteP, SerraoV,ApetatoM.Efficacy of narrowbandUVB vs.PUVA in
patientswith early-stagemycosis fungoides.
JEurAcadDermatolVenereol
.
2010;24(6):716-721.
21. Pothiawala SZ,BaldwinBT,CherpelisBS,LienMH, FenskeNA.The
role of phototherapy in cutaneousT-cell lymphoma.
JDrugsDermatol
.
2010;9(7):764-772.
22. HuskenAC,TsianakasA,HensenP, et al.Comparison of pegylated
interferon alpha-2bplus psoralenPUVA versus standard interferon alpha-
2a plus PUVA inpatientswith cutaneousT-cell lymphoma.
JEurAcad
DermatolVenereol
. 2012;26(1):71-78.
23. BookenN,WeissC,Utikal J, FelchtM,Goerdt S,KlemkeCD.
Combination therapywith extracorporeal photopheresis, interferon-alpha,
PUVA and topical corticosteroids in themanagement of Sezary syndrome.
JDtschDermatolGes
. 2010;8(6):428-438.
24. El-MoftyM,El-DaroutyM, SalonasM, et al.Narrow bandUVB (311
nm), psoralenUVB (311nm) andPUVA therapy in the treatment of
early-stagemycosis fungoides: a right-left comparative study.
Photodermatol
Photoimmunol Photomed
. 2005;21(6):281-286.
25. Morris SL. Skin lymphoma.
ClinOncol (RCollRadiol)
. 2012;24(5):371-
385.
26. PiccinnoR,CaccialanzaM,CukaE,Recalcati S.Localized conventional
radiotherapy in the treatment ofmycosis fungoides: our experience in 100
patients.
JEurAcadDermatolVenereol
. 2013;[Epub ahead of print].
27. JonesGW,Kacinski BM,WilsonLD, et al.Total skin electron radiation
in themanagement ofmycosis fungoides:Consensus of theEuropean
Organization forResearch andTreatment ofCancer (EORTC)Cutaneous
LymphomaProjectGroup.
JAmAcadDermatol
. 2002;47(3):364-370.
28. KleinRS,Dunlop JD, Samimi SS, et al. Improvement inperipheral blood
disease burden inpatientswithSezary syndrome and leukemicmycosis
fungoides after total skin electron beam therapy.
JAmAcadDermatol
.
2013;68(6):972-977.
29. MaingonP,TrucG,Dalac S, et al.Radiotherapy of advancedmycosis
fungoides: indications and results of total skin electron beam andphoton
beam irradiation.
RadiotherOncol
. 2000;54(1):73-78.
30. MicailyB,CampbellO,MoserC,VonderheidEC,BradyLW.Total skin
electron beam and total nodal irradiation of cutaneousT-cell lymphoma.
Int
JRadiatOncol Biol Phys
. 1991;20(4):809-813.
31. MicailyB,MoserC,VonderheidEC, et al.The radiation therapy of
early stage cutaneousT-cell lymphoma.
Int JRadiatOncol Biol Phys
.
1990;18(6):1333-1339.
32. LloydS,ChenZ, Foss FM,GirardiM,WilsonLD.Acute toxicity and risk
of infectionduring total skin electron beam therapy formycosis fungoides.
JAmAcadDermatol
. 2013;69(4):537-543.
33. HallahanDE,GriemML,GriemSF, et al.Combinedmodality therapy for
tumor stagemycosis fungoides: results of a 10-year follow-up.
JClinOncol
.
1988;6(7):1177-1183.
34. WilsonLD, JonesGW,KimD, et al.Experiencewith total skin electron
beam therapy in combinationwith extracorporeal photopheresis in the
management of patientswith erythrodermic (T4)mycosis fungoides.
JAm
AcadDermatol
. 2000;43(1Pt 1):54-60.
